2-[(4-甲基苯基)磺酰基-(2-苯基乙基)氨基]乙酸 | 66895-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[(4-甲基苯基)磺酰基-(2-苯基乙基)氨基]乙酸
• 英文名称: N-phenethyl-N-tosylglycine
• 英文别名: N-(2-phenylethyl)-N-[(4-methylphenyl)sulfonyl]glycine；N-phenethyl-N-(toluene-4-sulfonyl)-glycine；N-Phenaethyl-N-(toluol-4-sulfonyl)-glycin；2-[(4-Methylphenyl)sulfonyl-(2-phenylethyl)amino]acetic acid
• CAS: 66895-91-8
• 化学式: C₁₇H₁₉NO₄S
• 分子量: 333.408
• InChiKey: NLUNKKRKOJXXNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(4-甲基苯基)磺酰基-(2-苯基乙基)氨基]乙酸 在 氯化亚砜 作用下， 生成 3-(toluene-4-sulfonyl)-2,3,4,5-tetrahydro-benz[d]azepin-1-one-(2,4-dinitro-phenylhydrazone)
  参考文献：
  名称：

  444.氮杂苯并环庚酮。第二部分 芳基氨基酯的Dieckmann环化

  摘要：

  DOI：

  10.1039/jr9570002312
• 作为产物：
  描述：

  ethyl N-phenethyl-N-tosylglycinate 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 2-[(4-甲基苯基)磺酰基-(2-苯基乙基)氨基]乙酸
  参考文献：
  名称：

  [EN] BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  [FR] COMPOSÉS DE CARBAMOYLPYRIDONE TRICYCLIQUE PONTÉS ET LEUR UTILISATION PHARMACEUTIQUE

  摘要：

  本发明揭示了用于治疗或预防人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有以下式（I）：包括立体异构体和其药用可接受的盐，其中R1、R2、L、W1、W2、X、Y和Z如本文所定义。本发明还揭示了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。

  公开号：

  WO2020197991A1

文献信息

• Solid Phase Synthesis of N-Alkyl Sulfonamides
  作者：Sharon Dankwardt、David Smith、John Porco Jr.、Cindy Nguyen

  DOI：10.1055/s-1997-5776

  日期：1997.7

  Polymer-supported sulfonamides were alkylated using alkyl halides in the presence of DBU or with alcohols via the Mitsunobu reaction.

  聚合物支撑的磺酰胺在 DBU 存在下使用烷基卤化物进行烷基化，或通过 Mitsunobu 反应与醇进行烷基化。
• Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
  申请人：Gilead Sciences, Inc.

  公开号：US11084832B2

  公开（公告）日：2021-08-10

  Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明公开了用于治疗或预防人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有下式(I)： 其中 R1、R2、L、W1、W2、X、Y 和 Z 如本文所定义。此外，还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。
• Progresses in the pursuit of aldose reductase inhibitors: The structure-based lead optimization step
  作者：Anna Ramunno、Sandro Cosconati、Stefania Sartini、Vita Maglio、Sara Angiuoli、Valeria La Pietra、Salvatore Di Maro、Mariateresa Giustiniano、Concettina La Motta、Federico Da Settimo、Luciana Marinelli、Ettore Novellino

  DOI：10.1016/j.ejmech.2012.02.045

  日期：2012.5

  Aldose reductase (ALR2) is a crucial enzyme in the development of the major complications of diabetes mellitus. Very recently it has been demonstrated that the ARL2 inhibitor, fidarestat, significantly prevents inflammatory signals (TNF-alpha, LPS) that cause cancer (colon, breast, prostate and lung), metastasis, asthma, and other inflammatory diseases. Currently, fidarestat is in phase Ill clinical trial for diabetic neuropathy and was found to be safe. Thus the finding of novel, potent ARL2 inhibitors is today more than in the past in great demand as they can pave the way for a novel therapeutic approach for a number of diseases besides the diabetes. Herein, starting from the virtual screening-derived ALR2 inhibitor S12728 (1), a rational receptor-based lead optimization has been undertaken. The design and synthetic efforts here reported led to the discovery of several new compounds endowed with low micromolar/submicromolar activities. (C) 2012 Elsevier Masson SAS. All rights reserved.
• Budesinsky et al., Cesko-Slovenska Farmacie, 1959, vol. 8, p. 161,164
  作者：Budesinsky et al.

  DOI：——

  日期：——
• BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：GILEAD SCIENCES, INC.

  公开号：EP3938047A1

  公开（公告）日：2022-01-19